Sara Nayeem, MD, is a Partner at Avoro Capital Advisors (formerly Avoro Ventures). See sector focus and contact routes.
Sara Nayeem, MD, is a Partner at Avoro Capital Advisors (formerly Avoro Ventures), where she focuses on venture capital investments in biopharmaceuticals after joining the firm in February 2021 following a 12-year tenure as a Partner at New Enterprise Associates (NEA). Her investment thesis centers on biopharmaceutical companies across early-stage, late-stage, and crossover rounds, with a primary geographic focus on the United States. She typically deploys check sizes ranging from $100,000 to $10 million and has served as a board member for portfolio companies, indicating active involvement rather than purely follow-on behavior. Notable portfolio companies include Vanqua Bio, a biotechnology firm developing therapies for Parkinson’s disease where she serves on the board, and Scribe Therapeutics, a CRISPR-based molecular engineering company for which she acts as a board observer. Nayeem holds an MD and MBA from Yale University and a BA in Biology from Harvard, combining deep scientific expertise with institutional investment experience spanning nearly 20 years. While no public writing or distinctive published point of view is cited in available sources
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Washington when building a target list.
Investors like Sara Nayeem · Full investor directory · Investor access · Company funding database